KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Liabilities (2018 - 2025)

Adaptive Biotechnologies' Total Liabilities history spans 8 years, with the latest figure at $287.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 14.59% year-over-year to $287.7 million; the TTM value through Dec 2025 reached $287.7 million, down 14.59%, while the annual FY2025 figure was $287.7 million, 14.59% down from the prior year.
  • Total Liabilities for Q4 2025 was $287.7 million at Adaptive Biotechnologies, roughly flat from $286.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $396.4 million in Q3 2022 and bottomed at $286.4 million in Q3 2025.
  • The 5-year median for Total Liabilities is $340.6 million (2021), against an average of $337.3 million.
  • The largest annual shift saw Total Liabilities dropped 15.22% in 2022 before it rose 27.84% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $319.2 million in 2021, then rose by 22.95% to $392.5 million in 2022, then dropped by 10.1% to $352.9 million in 2023, then fell by 4.52% to $336.9 million in 2024, then fell by 14.59% to $287.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Total Liabilities are $287.7 million (Q4 2025), $286.4 million (Q3 2025), and $317.1 million (Q2 2025).